News | January 25, 2025
Mankind Pharma Q3 FY25 PAT dips 16% to Rs. 385 Cr
Q3 FY25 revenue up 24% to Rs 3,230 crore
Q3 FY25 revenue up 24% to Rs 3,230 crore
EBITDA margins expand to 31.3%
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Cenexi is committed to working closely with the ANSM to address the observations
Based on data, 1.75 mg/kg dose established as recommended dose for Phase 3 trial of this investigational antibody-drug conjugate
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
MedGenome reaffirms its commitment to broaden access to quality and affordable genetic solutions for all
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Subscribe To Our Newsletter & Stay Updated
